Although continuous hepatic artery infusions (CHAI) of (FUDR) Floxuridine have been effective in reducing the size of colorectal hepatic metastases the toxicity of the infusions have been high with almost a quarter of the patients developing biliary sclerosis. Techniques to lower toxicity, yet continue the beneficial antitumor effects, are being investigated. One suggested strategy is to change the flow pattern of the continuous infusion from a constant rate to a day cycled pattern. In this infusion a continuous rate is given over a 24 hour period with 60% of the infusion delivered between 3 PM and 9 PM and the least amount of infusion delivered between 3 AM and 9 PM. Previous research has suggested that this day cycle pattern will lower the toxicity of the infusion. This experiment is a test of "day cycled" continuous hepatic artery infusions in rats bearing hepatic metastases from a colon adenocarcinoma. Previous research from our laboratory has shown a lowered toxicity when the constant infusion was replaced with the day cycled pattern.
INTRODUCTION
Continuous hepatic artery infusions (CHAI) of floxuridine (FUDR) through an implantable pump was popularized as a treatment for hepatic metastases from colorectal cancer in the early 1980s. Although there was a wave of initial enthusiasm, this began to die down as it became clear that there were substantial toxicities that accompanied the significant benefits seen with this mode of therapy.
The most serious of the toxicities, biliary sclerosis, also known as sclerosing cholangitis, is a fibrosis of the bile ducts, usually at the hepatic duct bifurcation, seen mainly in patients who were responders to therapy1. given with the majority of the daily infusion delivered from 3PM to 9PM and the least delivered from 3AM to 9AM is less toxic than a constant continuous infusion5.
The concept of decreased toxicity with a "day cycle" circadian patterned continuous infusion has been utilized clinically for CHAI of FUDR for hepatic metastases from colorectal primaries5. These studies suggest that toxicity is lowered by using a circadian timed infusion and that antitumor efficacy is not compromised. survived the infusion with minimal pathological hepatic toxicity. When the infusion was given with a "night cycle" pattern, that is most of the infusion was given between 9PM and 3AM, it was more toxic with all animals dying at a mean of 5.5 days + 1.2 SD.
Using these results we went ahead to test the efficacy of circadian infusions against established metastatic colon adenocarcinomas transplanted into the liver. In these present experiments we have shown that day cycled infusions allow more FUDR to be given with lower toxicity and an equal antitumor effect. More specifically 15 mg/kg/d of FUDR was administered for a 14 day CHAI with no toxicity versus an 80% toxicity when 10 mg/kg/day were given using a constant CHAI pattern.
The timing of the "day cycle" was picked because of the previous work by Hrushevsky. The mechanism for the decreased toxicity is unknown but various hypotheses have been proposed. It is known that when 5FU is given with a continuous intravenous infusion the concentration of the drug in the blood varies with time during a 24 hour period7. It was discovered that the highest concentrations were at night. The mechanism for FU metabolism is mainly centered in the liver. Thus it seems that hepatic metabolism of this drug is higher during the day. This increase in hepatic metabolism during daylight hours may explain the results of the present experiment. With increased metabolism of the drug during the time of greatest exposure (during the day) the systemic toxicities would be decreased.
Because it is a regional infusion the tumor cells are being exposed to the FUDR at higher doses before it has been metabolized so the antitumor effect is not compromised by the increased metabolism.
Other variations known to occur with a circadian pattern include increased corticosteroid levels in the late afternoon (in rats) a, increased T lymphocyte release (at night), increased CD4 cell activation (in afternoon), and increased antigen recognition and destruction (in the morning)9. These changes might also effect toxicity and tumor response in a circadian pattern. Further work should be done to ascertain if the present "day cycle" circadian schedule is the best one for decreasing toxicity and if it is also the optimal one for antitumor effect. When these criteria have been worked out this modality will be ready to enter the clinical arena.
